ID

35252

Description

Study ID: 107191 Clinical Study ID: 107191 Study Title: A Phase IIb, controlled, randomised, multicenter, single blind study to demonstrate the Non-Inferiority of the low dose influenza vaccine with or without adjuvant AS03 compared with FluarixTM (GlaxoSmithKline Biologicals) administered intramuscularly in elderly >= 60 years. Patient Level Data: NA Clinicaltrials.gov Identifier: NA EudraCT Number: 2006-000939-97 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Candidate Influenza Vaccine GSK1247446A Trade Name: FluarixTM Study Indication: Influenza The following criteria should be checked at each visit/contact subsequent to the first visit. If any become applicable during the study, it will not require withdrawal of the subject from the study but may determine a subject’s evaluability in the according-to-protocol (ATP) analysis. Visit 1: Day 0, Pre vaccination Visit 2: Day 21, Post vaccination 1 Phone contact: Day 30, post vaccination 1 Visit 3: Day 180, post vaccination 1 Visit 1 and 2 are part of the study: "Demonstration of the Non-Inferiority of the Low Dose Influenza Vaccine Compared with Fluarix NCT00321373", GSK-Study-ID 107022.

Mots-clés

Versions (2)
  1. 22/02/2019 22/02/2019 -
  2. 25/02/2019 25/02/2019 - Sarah Riepenhausen
Détendeur de droits

GlaxoSmithKline

Téléchargé le

25 février 2019

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY-NC 3.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Demonstration of the Non-Inferiority of the Low Dose Influenza Vaccine Compared with Fluarix EudraCT Number 2006-000939-97

Anglais

Elimination Criteria

1 Formulaires  
  1. StudyEvent: ODM
    1. Elimination Criteria
Administrative Data
Description

Administrative Data

Alias
UMLS CUI-1
C1320722
Subject Number
Description

Subject Number

Type de données

integer

Alias
UMLS CUI [1]
C2348585
Assessment Date
Description

Assessment Date

Type de données

date

Alias
UMLS CUI [1]
C2985720
Elimination Criteria During the Study
Description

Elimination Criteria During the Study

Alias
UMLS CUI-1
C0680251
Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) during the study period.
Description

Use of Investigational or Non-Registered Product

Type de données

boolean

Alias
UMLS CUI [1,1]
C1524063
UMLS CUI [1,2]
C0013230
UMLS CUI [1,3]
C0347984
UMLS CUI [1,4]
C2347804
Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs during the study period. (For corticosteroids, this will mean prednisone, or equivalent, equal to 0.5 mg/kg/day or more. Inhaled and topical steroids are allowed.)
Description

Chronic Administation of Immunosuppressants or Immune-Modifying Drugs

Type de données

boolean

Alias
UMLS CUI [1,1]
C0021081
UMLS CUI [1,2]
C0205191
UMLS CUI [2,1]
C0005525
UMLS CUI [2,2]
C0205191
UMLS CUI [3,1]
C2064827
UMLS CUI [3,2]
C0332300
UMLS CUI [4,1]
C2065041
UMLS CUI [4,2]
C0332300
Administration of a vaccine not foreseen by the study protocol up to 30 days after vaccination and within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior the last study visit at Day 180
Description

Other Recent Vaccination

Type de données

boolean

Alias
UMLS CUI [1,1]
C0042196
UMLS CUI [1,2]
C0205394
UMLS CUI [1,3]
C0332185
Administration of a Flu vaccine during the study period.
Description

Administratino of Flu Vaccine

Type de données

boolean

Alias
UMLS CUI [1,1]
C0042200
UMLS CUI [1,2]
C1533734
UMLS CUI [1,3]
C0347984
UMLS CUI [1,4]
C2347804
Administration of immunoglobulins and/or any blood products during the study period.
Description

Administration of Immunoglobulins or Blood Products

Type de données

boolean

Alias
UMLS CUI [1,1]
C0021027
UMLS CUI [1,2]
C0347984
UMLS CUI [1,3]
C2347804
UMLS CUI [2,1]
C0371802
UMLS CUI [2,2]
C0347984
UMLS CUI [2,3]
C2347804
Newly confirmed or suspected immunosuppressive or immunodeficient condition.
Description

Confirmed or Suspected Immunosuppressive or Immunodeficient Condition

Type de données

boolean

Alias
UMLS CUI [1,1]
C0750484
UMLS CUI [1,2]
C0021051
UMLS CUI [2,1]
C4048329
UMLS CUI [2,2]
C0242114
UMLS CUI [3,1]
C0750484
UMLS CUI [3,2]
C4048329
UMLS CUI [4,1]
C0021051
UMLS CUI [4,2]
C0242114
Retour au début de la page

Similar models

Elimination Criteria

1 Formulaires
  1. StudyEvent: ODM
    1. Elimination Criteria
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
Administrative Data
C1320722 (UMLS CUI-1)
Subject Number
Item
Subject Number
integer
C2348585 (UMLS CUI [1])
Assessment Date
Item
Assessment Date
date
C2985720 (UMLS CUI [1])
Item Group
Elimination Criteria During the Study
C0680251 (UMLS CUI-1)
Use of Investigational or Non-Registered Product
Item
Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) during the study period.
boolean
C1524063 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
C0347984 (UMLS CUI [1,3])
C2347804 (UMLS CUI [1,4])
Chronic Administation of Immunosuppressants or Immune-Modifying Drugs
Item
Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs during the study period. (For corticosteroids, this will mean prednisone, or equivalent, equal to 0.5 mg/kg/day or more. Inhaled and topical steroids are allowed.)
boolean
C0021081 (UMLS CUI [1,1])
C0205191 (UMLS CUI [1,2])
C0005525 (UMLS CUI [2,1])
C0205191 (UMLS CUI [2,2])
C2064827 (UMLS CUI [3,1])
C0332300 (UMLS CUI [3,2])
C2065041 (UMLS CUI [4,1])
C0332300 (UMLS CUI [4,2])
Other Recent Vaccination
Item
Administration of a vaccine not foreseen by the study protocol up to 30 days after vaccination and within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior the last study visit at Day 180
boolean
C0042196 (UMLS CUI [1,1])
C0205394 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,3])
Administratino of Flu Vaccine
Item
Administration of a Flu vaccine during the study period.
boolean
C0042200 (UMLS CUI [1,1])
C1533734 (UMLS CUI [1,2])
C0347984 (UMLS CUI [1,3])
C2347804 (UMLS CUI [1,4])
Administration of Immunoglobulins or Blood Products
Item
Administration of immunoglobulins and/or any blood products during the study period.
boolean
C0021027 (UMLS CUI [1,1])
C0347984 (UMLS CUI [1,2])
C2347804 (UMLS CUI [1,3])
C0371802 (UMLS CUI [2,1])
C0347984 (UMLS CUI [2,2])
C2347804 (UMLS CUI [2,3])
Confirmed or Suspected Immunosuppressive or Immunodeficient Condition
Item
Newly confirmed or suspected immunosuppressive or immunodeficient condition.
boolean
C0750484 (UMLS CUI [1,1])
C0021051 (UMLS CUI [1,2])
C4048329 (UMLS CUI [2,1])
C0242114 (UMLS CUI [2,2])
C0750484 (UMLS CUI [3,1])
C4048329 (UMLS CUI [3,2])
C0021051 (UMLS CUI [4,1])
C0242114 (UMLS CUI [4,2])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial